RNAM

Avidity Biosciences

Fundamental data last updated:March 2, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

74

Business Summary

Avidity Biosciences is a biotechnology company focused on developing RNA-based therapeutics. It works on advancing treatments designed to address serious diseases through targeted molecular approaches.

 


Analyze RNAM on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$11,246

Forward P/E

-

PEG

-

PRICE TO SALES

454.6

PRICE TO BOOK

6

EV / EBITDA

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$4.19

Next Year EPS Growth Estimate

-

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

-29.10%

FREE CASH FLOW

Operating Margin

-2934.90%

Debt-to-Equity

0

Piotroski F-Score

Altman Z-Score

Return on Invested Capital (ROIC)

Current Ratio

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze RNAM on TradingView

Gainseekers Quantitative Analysis

Summary

Avidity Biosciences is a Nasdaq-listed biotechnology company with a market capitalization of $11,246 million. The company is currently unprofitable, reporting EPS of -$4.19, a return on equity of -29.10%, and an operating margin of -2934.90%. It trades at a very high Price/Sales ratio of 454.6 and a Price/Book ratio of 6, with its next earnings report expected in 74 days.

AI Exposure / Tech Reliance

As a biotechnology company within the healthcare sector, Avidity Biosciences relies heavily on advanced scientific and technical innovation to develop its therapeutic pipeline. Its value is closely tied to research-driven breakthroughs rather than current earnings generation.

The Bull Case

The company carries no debt, with a Debt/Equity ratio of 0, which provides financial flexibility. Additionally, the mean consensus target price of $73.83 suggests potential upside depending on clinical and operational progress.

The Bear Case

The company is deeply unprofitable, with negative EPS of -$4.19 and an operating margin of -2934.90%, indicating substantial ongoing losses. Its extremely high Price/Sales ratio of 454.6 may reflect elevated valuation risk relative to its current revenue base.

Market Sentiment & Smart Money

Short Interest %

-

Analyst Consensus

2.63

Average Analyst Price Target

$73.83

Institutional Ownership %

-

1-Year Beta

Insider Buying % (6 Mo)

Distance to 52-Week High

Distance to 52-Week Low

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.